Next-Generation Cancer Diagnostics
SKU
MRR-AD36CD898567
Region
Global
Publication Date
February 2024
Delivery
Immediate
2022
USD 7.96 billion
2030
USD 44.36 billion
2023
USD 9.77 billion
CAGR
23.93%
Next-Generation Cancer Diagnostics Market by Technology (Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics, DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR), Cancer Type (Bladder Cancer, Breast Cancer, Cervical Cancer), Application, Function - Global Forecast 2023-2030

[181 Pages Report] The Next-Generation Cancer Diagnostics Market size was estimated at USD 7.96 billion in 2022 and expected to reach USD 9.77 billion in 2023, at a CAGR 23.93% to reach USD 44.36 billion by 2030.

Next-Generation Cancer Diagnostics Market
To learn more about this report, request a free sample copy

The next-generation cancer diagnostics market encompasses the latest technological advancements in the tools, techniques, and methodologies utilized to detect and characterize cancers. This market focuses on innovations that offer enhanced accuracy, sensitivity, and specificity compared to traditional diagnostic methods. It includes genomic, proteomic, and epigenomic analysis, imaging techniques, and bioinformatics tools for early detection, prognosis, and cancer treatment monitoring. Several factors drive the expansion of next-generation cancer diagnostics, including the increasing global prevalence of cancer, advancements in genomic sequencing technologies, and the growing emphasis on personalized medicine. Furthermore, government initiatives and funding for cancer research contribute significantly to market growth. Integrating artificial intelligence and machine learning in diagnostics also presents opportunities for enhanced precision in cancer detection and prognosis. Despite the promising development, the next-generation cancer diagnostics market faces several limitations and challenges. High costs associated with advanced diagnostic technologies can limit access to these tools, particularly in low- and middle-income countries. Moreover, the complexity of cancer biology and the variability in tumor types pose challenges in developing universally effective diagnostic solutions. Regulatory hurdles and the need for robust clinical validation also slow down the market's pace of innovation. However, recent developments in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and non-invasive imaging techniques have opened new avenues for early cancer detection and monitoring. These advancements present significant opportunities for market growth. Moreover, the application of next-generation sequencing (NGS) in cancer diagnostics continues to evolve, offering the potential to discover novel biomarkers and therapeutic targets.

Next-Generation Cancer Diagnostics Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer

Clustered regularly interspaced short palindromic repeats diagnostics technology presents a revolutionary approach to cancer diagnostics, leveraging its gene editing capabilities to detect cancer mutations precisely. This technique offers the potential for rapid, accurate, and cost-effective diagnostics, fundamentally changing how cancers are identified and treated. DNA microarrays enable the simultaneous analysis of thousands of DNA sequences in a single experiment. This technology is used in cancer diagnostics to identify gene mutations and expressions specific to different cancer types, facilitating personalized treatment plans. Lab-on-a-chip integrates multiple laboratory processes into a single chip, offering a compact and efficient solution for cancer diagnostics. Combined with RT-PCR, a method that measures gene expression, it provides a powerful tool for detecting and quantifying cancer markers at the molecular level. Molecular diagnostics involves analyzing DNA or RNA sequences to identify cancer-related mutations. This segment emphasizes the importance of genetic analysis in the early detection, classification, and management of cancer, offering a tailored approach to therapy. NGS offers comprehensive genomic profiling by sequencing millions of DNA fragments in parallel. This technology provides deep insights into the genetic mutations that cause cancer, allowing for the identification of targeted therapies and better outcomes for patients. Protein microarrays analyze the expression and interaction of proteins on a large scale. In cancer diagnostics, they are used to study protein changes caused by cancer, aiding in discovering new biomarkers for early detection and treatment strategies. Quantitative Polymerase Chain Reaction (qPCR) is a technique that amplifies and quantifies a targeted DNA molecule. Multiplexing, simultaneously measuring multiple analytes, enhances qPCR's capability in cancer diagnostics, allowing for detecting multiple genes associated with cancer in a single test.

Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments

Cancer screening represents the first line of defense in combating cancer, utilizing next-generation diagnostic technologies to identify the presence of cancer in individuals showing no apparent symptoms. This segment focuses on early cancer detection, aiming to diagnose diseases at a stage where they are more likely to be treated successfully. Advanced imaging technologies, molecular diagnostics, and biomarker assessment are tools used to enhance cancer screening efficacy. Companion diagnostics are specialized tests designed to identify patients most likely to benefit from a targeted therapy. This segment plays a critical role in personalized medicine by determining the presence of specific genetic or molecular markers that predict how well a patient will respond to targeted therapy options. In the context of next-generation cancer diagnostics, this often involves using genomic profiling to tailor treatment strategies to the individual's cancer. Prognostic tools in next-generation cancer diagnostics are employed to predict cancer's likely course and outcome in diagnosed patients. This segment helps in assessing disease aggression, the risk of recurrence, and overall survival expectations. By leveraging advanced genomic and proteomic analysis, prognostic diagnostics aid in making informed decisions regarding the necessity and intensity of therapeutic interventions, ultimately guiding patient management plans. Risk analysis in next-generation cancer diagnostics focuses on assessing an individual's risk of developing cancer based on genetic, environmental, and lifestyle factors. This segment utilizes various genetic testing and biomarker evaluation methods to identify individuals at higher risk for developing specific cancers, potentially leading to targeted preventive measures or more frequent and detailed surveillance programs. Therapeutic monitoring involves using next-generation diagnostic tools to track the effectiveness of cancer treatments and monitor for signs of disease progression or recurrence. This application segment is crucial for adjusting treatment plans in real time, managing side effects, and improving patient outcomes. Through the employment of circulating tumor DNA (ctDNA), imaging technologies, and other biomarkers, therapeutic monitoring provides detailed insights into the tumor's response to treatment and facilitates personalized treatment adjustments.

Regional Insights

In the Americas, particularly the United States, next-generation cancer diagnostics are experiencing rapid advancements, largely driven by significant investments in research and development. The focus is largely on precision medicine and non-invasive diagnostic techniques, such as liquid biopsies that detect circulating tumor DNA. The EMEA region shows a diverse landscape in adopting and developing next-generation cancer diagnostics. Europe leads within the region, with several countries incorporating genomic sequencing and biomarker analysis into standard cancer care, supported by strong healthcare systems and public healthcare policies. The Middle East, particularly countries such as Israel and the United Arab Emirates, are rapidly emerging as innovative hubs for medical technology, including cancer diagnostics. Africa faces more challenges, including resource limitations, but progress is being made through international partnerships and initiatives to improve cancer care infrastructure and accessibility. The Asia-Pacific region is witnessing significant growth in the next-generation cancer diagnostics market, driven by rising cancer prevalence, growing healthcare expenditure, and a surge in awareness about early cancer detection. Japan, South Korea, China, and Australia are at the forefront, investing heavily in healthcare technology and research. China, in particular, has seen rapid advancements and high adoption rates of technologies such as AI-driven diagnostic tools. Additionally, the region benefits from several fast-growing biotech startups and strategic collaborations between global and local firms aiming to tailor cancer diagnostics to regional specificities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Genialis to Develop Biomarker-Based Cancer Diagnostic Models

    Genialis, an AI-driven life sciences company, is working to develop the next generation of cancer diagnostics based on biomarkers. Through a targeted approach to cancer detection, these models can accurately identify and track cancer at the cellular level in order to make more individualized diagnoses. In addition to improving accuracy, these biomarker models are expected to reduce diagnostic costs and improve patient outcomes. As the field of personalized, precision oncology continues to grow, Genialis' work in developing biomarker-based diagnostic models has the potential to revolutionize how healthcare providers detect and treat cancer. [Published On: 2023-03-30]

  • Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies

    Thermo Fisher Scientific Inc. strategic collaboration to support clinical manufacturing of T-cell therapies. This union aims to unlock the power of next-generation cancer diagnostics, further therapy development, and increase access to curative drugs. Through this collaboration, both industry-leading companies will bring their expertise in process optimization, CMC development, and cell engineering to maximize production efficiency through automation and high-quality processes. This collective vision for better health outcomes indicates the ambition to develop more personalized treatments for cancer patients. [Published On: 2023-03-29]

  • Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition

    Pfizer acquired cancer-focused biotechnology firm Seagen for a notable sum of USD 43 billion, positioning itself as a formidable player in the oncology field. Emphasizing the significance of innovation in cancer treatment, the acquisition notably enhances Pfizer's oncology portfolio by incorporating Seagen's advanced antibody-drug conjugate (ADC) technology. ADCs represent a rapidly expanding segment within cancer therapeutics, renowned for their precision in targeting and eradicating cancer cells while minimizing damage to surrounding healthy tissues. [Published On: 2023-03-13]

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMérieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
    • DNA Microarrays
    • Lab-on-a-Chip & Reverse Transcriptase-PCR
    • Molecular Diagnostics
    • Next Generation Sequencing
    • Protein Microarrays
    • qPCR & Multiplexing
  • Cancer Type
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Thyroid Cancer
    • Uterine Cancer
  • Application
    • Cancer Screening
    • Companion Diagnostics
    • Prognostics
    • Risk Analysis
    • Therapeutic Monitoring
  • Function
    • Biomarker Development
    • CTC Analysis
    • Epigenetic Analysis
    • Genetic Analysis
    • Proteomic Analysis

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Next-Generation Cancer Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Cancer Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the Next-Generation Cancer Diagnostics Market?
  4. What is the market share of the leading vendors in the Next-Generation Cancer Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the Next-Generation Cancer Diagnostics Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageNEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
    2. Next-Generation Cancer Diagnostics Market, by RegionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsNEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
      1. Drivers
        1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
        2. Growing Utilization of Microfluidic Chips in Cancer Management
        3. Government Initiatives Towards Cancer Screening
      2. Restraints
        1. High Investment and Insufficient Standardization of Diagnostics
      3. Opportunities
        1. Proliferation of Personalized and Advanced Genome Medicine
        2. Technological Advancements in Next-Generation Cancer Diagnostics
      4. Challenges
        1. Limitations and Risks Associated with NGC Diagnostics
    2. Market Segmentation Analysis
      1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
      2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
    3. Market Trend Analysis
    4. Cumulative Impact of COVID-19
    5. Cumulative Impact of Russia-Ukraine Conflict
    6. Cumulative Impact of High Inflation
    7. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    8. Value Chain & Critical Path Analysis
    9. Regulatory Framework
    10. Client Customization
  6. Next-Generation Cancer Diagnostics Market, by Technology
    1. IntroductionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
    2. Clustered Regularly Interspaced Short Palindromic Repeats DiagnosticsNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY , 2018-2030 (USD MILLION)
    3. DNA MicroarraysNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY , 2018-2030 (USD MILLION)
    4. Lab-on-a-Chip & Reverse Transcriptase-PCRNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY , 2018-2030 (USD MILLION)
    5. Molecular DiagnosticsNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY , 2018-2030 (USD MILLION)
    6. Next Generation SequencingNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY , 2018-2030 (USD MILLION)
    7. Protein MicroarraysNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY , 2018-2030 (USD MILLION)
    8. qPCR & MultiplexingNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY , 2018-2030 (USD MILLION)
  7. Next-Generation Cancer Diagnostics Market, by Cancer Type
    1. IntroductionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
    2. Bladder CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY , 2018-2030 (USD MILLION)
    3. Breast CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY , 2018-2030 (USD MILLION)
    4. Cervical CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY , 2018-2030 (USD MILLION)
    5. Colorectal CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY , 2018-2030 (USD MILLION)
    6. Kidney CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY , 2018-2030 (USD MILLION)
    7. Lung CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY , 2018-2030 (USD MILLION)
    8. Pancreatic CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY , 2018-2030 (USD MILLION)
    9. Prostate CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY , 2018-2030 (USD MILLION)
    10. Thyroid CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY , 2018-2030 (USD MILLION)
    11. Uterine CancerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY , 2018-2030 (USD MILLION)
  8. Next-Generation Cancer Diagnostics Market, by Application
    1. IntroductionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    2. Cancer ScreeningNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY , 2018-2030 (USD MILLION)
    3. Companion DiagnosticsNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY , 2018-2030 (USD MILLION)
    4. PrognosticsNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY , 2018-2030 (USD MILLION)
    5. Risk AnalysisNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY , 2018-2030 (USD MILLION)
    6. Therapeutic MonitoringNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY , 2018-2030 (USD MILLION)
  9. Next-Generation Cancer Diagnostics Market, by Function
    1. IntroductionNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    2. Biomarker DevelopmentNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY , 2018-2030 (USD MILLION)
    3. CTC AnalysisNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY , 2018-2030 (USD MILLION)
    4. Epigenetic AnalysisNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY , 2018-2030 (USD MILLION)
    5. Genetic AnalysisNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY , 2018-2030 (USD MILLION)
    6. Proteomic AnalysisNEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY , 2018-2030 (USD MILLION)
  10. Americas Next-Generation Cancer Diagnostics Market
    1. Introduction
    2. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    3. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    14. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  11. Asia-Pacific Next-Generation Cancer Diagnostics Market
    1. Introduction
    2. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    6. China
    7. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    8. India
    9. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  13. Competitive Landscape
    1. FPNV Positioning MatrixNEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerNEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
      2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
      3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
      4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
      5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
      6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
  14. Competitive Portfolio
    1. Key Company Profiles
      1. Abbott Laboratories
      2. Adaptive Biotechnologies Corporation
      3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
      4. Agilent Technologies, Inc.
      5. Akadeum Life Sciences
      6. Almac Group
      7. Becton, Dickinson & Company
      8. Bio-Techne Corporation
      9. Biological Dynamics Inc.
      10. bioMérieux SA
      11. BioNTech SE
      12. Castle Biosciences Inc.
      13. Danaher Corporation
      14. Exact Sciences Corporation
      15. F. Hoffmann-La Roche Ltd.
      16. GE HealthCare
      17. Hologic Inc.
      18. Illumina, Inc.
      19. Johnson & Johnson Services, Inc.
      20. Konica Minolta, Inc.
      21. Koninklijke Philips N.V.
      22. NeoGenomics Laboratories
      23. Novartis AG
      24. OPKO Health, Inc.
      25. Oxford Nanopore Technologies Limited
      26. Perkin Elmer, Inc.
      27. Qiagen N.V.
      28. Siemens Healthineers AG
      29. Sysmex Corporation
      30. Telerad Tech
      31. Thermo Fisher Scientific, Inc.
    2. Key Product Portfolio
  1. Abbott Laboratories
  2. Adaptive Biotechnologies Corporation
  3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  4. Agilent Technologies, Inc.
  5. Akadeum Life Sciences
  6. Almac Group
  7. Becton, Dickinson & Company
  8. Bio-Techne Corporation
  9. Biological Dynamics Inc.
  10. bioMérieux SA
  11. BioNTech SE
  12. Castle Biosciences Inc.
  13. Danaher Corporation
  14. Exact Sciences Corporation
  15. F. Hoffmann-La Roche Ltd.
  16. GE HealthCare
  17. Hologic Inc.
  18. Illumina, Inc.
  19. Johnson & Johnson Services, Inc.
  20. Konica Minolta, Inc.
  21. Koninklijke Philips N.V.
  22. NeoGenomics Laboratories
  23. Novartis AG
  24. OPKO Health, Inc.
  25. Oxford Nanopore Technologies Limited
  26. Perkin Elmer, Inc.
  27. Qiagen N.V.
  28. Siemens Healthineers AG
  29. Sysmex Corporation
  30. Telerad Tech
  31. Thermo Fisher Scientific, Inc.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Next-Generation Cancer Diagnostics Market
The Global Next-Generation Cancer Diagnostics Market size was estimated at USD 7.96 billion in 2022 and expected to reach USD 9.77 billion in 2023.
The Global Next-Generation Cancer Diagnostics Market to grow USD 44.36 billion by 2030, at a CAGR of 23.93%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.